Yidu Tech (HKSE:02158) ROCE % : -6.61% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Yidu Tech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Yidu Tech's annualized ROCE % for the quarter that ended in Mar. 2024 was -6.61%.

Yidu Tech ROCE % Historical Data

The historical data trend for Yidu Tech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yidu Tech ROCE % Chart

Yidu Tech Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

-255.81

-17.36

-14.41

-5.06

Yidu Tech Semi-Annual Data
	Mar18	Mar19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
ROCE %	Get a 7-Day Free Trial							-16.26	-13.15	-3.56	-6.61	-2.71

Yidu Tech ROCE % Calculation

Yidu Tech's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	-236.686	/	( ( (5594.183 - 764.272)	+	(5240.533 - 710.979) )	/ 2 )
	=	-236.686	/	( (4829.911	+	4529.554)	/ 2 )
	=	-236.686	/	4679.7325
	=	-5.06 %

Yidu Tech's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Sep. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Sep. 2023 )		(Q: Mar. 2024 )
	=	-302.954	/	( ( (5211.718 - 575.027)	+	(5240.533 - 710.979) )	/ 2 )
	=	-302.954	/	( ( 4636.691	+	4529.554 )	/ 2 )
	=	-302.954	/	4583.1225
	=	-6.61 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2024) EBIT data.

Yidu Tech (HKSE:02158) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Yidu Tech ROCE % Related Terms

Thank you for viewing the detailed overview of Yidu Tech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Yidu Tech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Yidu Tech Inc (HKSE:02158) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0EL:Germany

Address

No.9 Building of Huayuan North Road, 8th Floor Health Work, Haidian District, Beijing, CHN

Website

https://www.yidutechgroup.com

Yidu Tech offers healthcare Big Data. It is an AI cloud-based firm providing solutions and tools to aid in more informed decisions to drive better efficiency in clients' strategies. Its clients are hospitals, pharmaceutical, biotech and medical device firms, research institutions, insurance companies, patients, and regulators. It three business segments are: Big Data platform and solutions, which partners with hospitals and policymakers to drive better efficiency; life sciences solutions, which enables better probability of clinical trial success with less drug development time and cost; and health management solutions, which helps with patient management. The Big Data platform accounted for 40% of its revenue in 2024 and it is its core business.

Executives

Gong Yingying	2202 Interest of your spouse
Xu Jiming	2101 Beneficial owner
Brunei Investment Agency	2101 Beneficial owner
Gic Private Limited	2102 Investment manager
Sweet Panda Limited	2101 Beneficial owner

Yidu Tech Headlines

No Headlines